RFPL3 Inhibitors
RFPL3 inhibitors belong to a specific chemical class of compounds that are designed to target and modulate the activity of the RFPL3 protein. RFPL3, which stands for "Ring Finger Protein-Like 3," is a protein encoded by the RFPL3 gene. This protein plays a significant role in various cellular processes, primarily in the regulation of protein degradation and turnover within the cell. The chemical class of RFPL3 inhibitors has garnered attention in the field of molecular biology and biochemistry due to their selectively inhibit the function of RFPL3. These inhibitors are designed to interfere with the activity of RFPL3, thereby influencing the ubiquitin-proteasome pathway, a critical mechanism responsible for the degradation of proteins in the cell.
The mechanism of action of RFPL3 inhibitors typically involves binding to specific regions of the RFPL3 protein, disrupting its function, and ultimately affecting protein degradation processes. This class of compounds has gained significance in research settings, as they enable scientists to explore the intricate regulatory networks governing protein homeostasis within cells. By inhibiting RFPL3, researchers can investigate the downstream effects on protein stability, turnover, and cellular processes, shedding light on the functional roles of this protein.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Fludarabine | 21679-14-1 | sc-204755 sc-204755A | 5 mg 25 mg | $57.00 $200.00 | 15 | |
Fludarabine inhibits RFPL3 by interfering with DNA synthesis and repair, ultimately leading to cell cycle arrest and apoptosis in cancer cells. | ||||||
Gemcitabine Hydrochloride | 122111-03-9 | sc-204763 sc-204763A | 25 mg 100 mg | $94.00 $283.00 | 13 | |
Gemcitabine inhibits RFPL3 by incorporating into DNA strands during replication, causing chain termination and cell death in rapidly dividing cancer cells. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $76.00 $216.00 | 101 | |
Cisplatin forms covalent cross-links with DNA, leading to DNA damage and cell cycle arrest. RFPL3 is indirectly inhibited due to its role in DNA repair pathways. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $36.00 $149.00 | 11 | |
5-Fluorouracil interferes with RNA and DNA synthesis by inhibiting thymidylate synthase, indirectly affecting RFPL3 through disruptions in nucleotide metabolism. | ||||||
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $173.00 $418.00 | 43 | |
Doxorubicin intercalates with DNA, inhibiting DNA and RNA synthesis, which indirectly affects RFPL3's function in RNA processing. | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $92.00 $209.00 | 33 | |
Methotrexate inhibits dihydrofolate reductase, leading to decreased availability of nucleotide precursors, indirectly affecting RFPL3's role in RNA synthesis. | ||||||
Topotecan | 123948-87-8 | sc-338718 | 100 mg | $571.00 | ||
Topotecan inhibits topoisomerase I, causing DNA damage and cell cycle arrest, ultimately affecting RFPL3's function in RNA processing. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $57.00 $182.00 $92.00 | 21 | |
Camptothecin inhibits topoisomerase I, leading to DNA strand breaks, cell cycle arrest, and disruptions in RNA processing by RFPL3. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $73.00 $238.00 $717.00 $2522.00 $21420.00 | 53 | |
Actinomycin D binds to DNA, preventing RNA polymerase activity and indirectly inhibiting RFPL3's role in RNA processing. | ||||||
Mitomycin C | 50-07-7 | sc-3514A sc-3514 sc-3514B | 2 mg 5 mg 10 mg | $65.00 $99.00 $140.00 | 85 | |
Mitomycin C cross-links DNA, leading to DNA damage and cell cycle arrest, indirectly affecting RFPL3's function in RNA processing. | ||||||